Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.

Sara Ribeirinho-SoaresDiana PáduaAna Luísa AmaralElvia ValentiniDaniela AzevedoCristiana MarquesRita BarrosFilipa MacedoPatrícia MesquitaRaquel Almeida

Published in: BMC cancer (2021)

In conclusion, we observe that patients with stage II CRC with low expression of MUC2 in the tumor respond better when treated with adjuvant chemotherapy. This observation supports that MUC2 is involved in resistance to fluorouracil-based adjuvant chemotherapy and might be a promising future predictive biomarker in stage II CRC patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
poor prognosis
stem cells
prognostic factors
transcription factor
peritoneal dialysis
current status